Updated Jul 16, 2026
Ho Carole has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $52K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-08 | RPRX | Royalty Pharma plc | A — Grant or award | 4.5K | $0.00 | |
| 2025-08-12 | DNLI | Denali Therapeutics Inc. | S — Open-market sale | 806 | $14.64 | $12K |
| 2025-08-12 | DNLI | Denali Therapeutics Inc. | S — Open-market sale | 2.9K | $13.58 | $40K |
| 2025-08-05 | DNLI | Denali Therapeutics Inc. | M — Option exercise | 44.7K | $0.68 | $30K |
| 2025-07-31 | RPRX | Royalty Pharma plc | A — Grant or award | 5.8K | $0.00 | |
| 2025-07-31 | RPRX | Royalty Pharma plc | A — Grant or award | 2.8K | $0.00 | |
| 2024-11-27 | DNLI | Denali Therapeutics Inc. | M — Option exercise | 17.8K | $0.68 | $12K |
Ho Carole is a corporate insider — currently tracked as Director of Royalty Pharma plc (RPRX). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($52K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ho Carole profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.